ArticleJournal of contemporary brachytherapy2020
High-dose-rate brachytherapy using Leipzig applicators for non-melanoma localized skin cancer.
Article in Journal of contemporary brachytherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- Efficacy and Safety of Epidermal Radionuclide Therapy withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- HDR Brachytherapy in the Treatment of Skin Kaposi Sarcoma: A Mono-Institutional Series.Cancers · 2026Article
- HDR Mould-Based Brachytherapy for Cutaneous Neoplasms: Toxicity, Long-Term Control, Cosmesis and PROMs.Dermatology and therapy · 2026Article
- Brachytherapy and 3D printing for skin cancer: A review paper.Journal of contemporary brachytherapy · 2024Review
- Non-melanoma skin cancer treated with hypofractionated 192-Ir contact brachitherapy: a single institution series.Frontiers in oncology · 2024Article
- High-dose-rate skin brachytherapy with interstitial, surface, or a combination of interstitial and surface mold technique.Journal of contemporary brachytherapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTechnological advances with commercial production of surface applicators allowed high-dose-rate (HDR) afterloading brachytherapy to overpass challenges associated with the delivery of superficial radiation when treating non-melanoma skin cancer (NMSC). We reviewed our single institutional experience using HDR to treat basal (BCC) and squamous cell (SCC) carcinomas. MATERIAL AND
methodsA retrospective review of all patients treated with HDR and Leipzig-style applicators for NMSC at the Radiation Oncology Department, AC Camargo Cancer Center, from March 2013 to December 2018 was performed.
resultsSeventy-one patients with 101 lesions (BCCs, 69.3% or
conclusionsHDR offers a convenient treatment schedule for patients and is associated with excellent LC. The most effective regimen, in terms of dose and fractionation, to treat superficial NMSC with HDR remains uncertain, but a moderate minimum EQD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.